瑞舒伐他汀对老年患者颈动脉内膜中层厚度的影响

Effect of Rosuvastatin on Carotid Arterial Intima-media Thickness of Elderly Patients

目的:观察瑞舒伐他汀对老年患者颈动脉内膜中层厚度(CIMT)的影响,并与辛伐他汀相比较。方法:入选我院2008年1～8月住院的高龄老人高血脂患者126例,年龄全部>70岁,平均年龄(78.9±8.8)岁,均为男性。将126例患者随机分为治疗组与对照组,均继续原发病常规治疗,停用其他降脂药2周。治疗组使用瑞舒伐他汀5mg·d^(-1),对照组使用辛伐他汀10mg·d^(-1),入选当时及治疗8周后以超声观察CIMT的变化。结果:瑞舒伐他汀组治疗后,患者CIMT从(1.58±0.24)mm下降至(1.44±0.22)mm(P<0.01);与辛伐他汀组比较,差异无统计学意义(P>0.05)。所有患者对瑞舒伐他汀均能很好地耐受,依从性较好,研究期间未发现药物相关严重不良反应。结论:瑞舒伐他汀降脂治疗降低老年患者的CIMT,与辛伐他汀效果相似,具有良好的安全性。

Objective：To investigate the effect of rosuvastatin on carotid arterial intima-media thickness of elderly patients and its comparison with simvastatin.Method：126 patients hospitalized during January and August 2008 were randomly divided into a treatment group and a cotrolled group.All the patients were male and older than 70 years old,and their mean age was 78.9±8.8 years.63 patients accepted the rosovastatin therapy and 63 patients accepted the simvastatin therapy.Result：After 8-weeks therapy,CIMT was reduced from 1.58 ±0. 24mm before the treatment to 1.44± 0. 22mm after it. There was no difference between the two groups in decreasing CIMT. No adverse events related to the study medication were observed. Conclusion： The treatment with rsuvastatin can prevent the increase of carotid arteriosclerosis in eldlerly patients without any difference in decreasing CIMT, compared with simvastatin.